The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.

It’s clear there’s a strong connection between sustained earnings growth and hall-of-fame returns. On that note, here are three market-beating stocks with room for further growth.

Meta (META)

Five-Year Return: +147%

Famously founded by Mark Zuckerberg in his Harvard dorm, Meta Platforms (NASDAQ: META) operates a collection of the largest social networks in the world - Facebook, Instagram, WhatsApp, and Messenger, along with its metaverse focused Reality Labs.

Why Will META Outperform?

1. Customer spending is rising as the company has focused on monetization over the last two years, leading to 14.8% annual growth in its average revenue per user
2. Share repurchases over the last three years enabled its annual earnings per share growth of 51.3% to outpace its revenue gains
3. Strong free cash flow margin of 26.2% enables it to reinvest or return capital consistently, and its recently improved profitability means it has even more resources to invest or distribute

At $657.96 per share, Meta trades at 12.1x forward EV/EBITDA. Is now a good time to buy? Find out in our full research report, it’s free.

Axon (AXON)

Five-Year Return: +119%

Providing body cameras and tasers for first responders, AXON (NASDAQ: AXON) develops technology solutions and weapons products for military, law enforcement, and civilians.

Why Is AXON a Top Pick?

1. Products are reaching more customers as its unit sales averaged 26.3% growth over the past two years
2. Operating profits increased over the last five years as the company gained some leverage on its fixed costs and became more efficient
3. Earnings per share grew by 35.2% annually over the last two years and trumped its peers

Axon’s stock price of $399.45 implies a valuation ratio of 62.4x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it’s free.

Medpace (MEDP)

Five-Year Return: +253%

Founded in 1992 as a scientifically-driven alternative to traditional contract research organizations, Medpace (NASDAQ: MEDP) provides outsourced clinical trial management and research services to help pharmaceutical, biotechnology, and medical device companies develop new treatments.

Why Is MEDP Interesting?

1. Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 15.2% over the past two years
2. Market share is on track to rise over the next 12 months as its 17.9% projected revenue growth implies demand will accelerate from its two-year trend
3. Share buybacks catapulted its annual earnings per share growth to 34.2%, which outperformed its revenue gains over the last five years

Medpace is trading at $539.73 per share, or 35.2x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

Stocks We Like Even More

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.